(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Grasping the Basics of Business Land Regulation - 2Figure out How to Recognize Early Indications of Depressions
- 3A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- 4Israel issues notice that Ben-Gurion Airport flights likely restricted until at least April 16
- 5Manual for Picking the Ideal Wine Matching
- Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- IDF strikes Hamas terror base in Lebanon, Health Ministry says 11 killed
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
- Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- ABC News' Sam Champion opens up about recent health scare
- France, Germany, Italy summon Iranian envoys over 'unbearable, inhumane' regime crackdown
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
